Aim: To compare hepatic stiffness and fat fraction in patients with obesity and type 1 diabetes (T1D) with type 2 diabetes (T2D) with a similar body mass index (BMI).
Methods: In this prospective cross-sectional study, 90 participants with T1D (BMI 30.5 ± 4.5 kg/m; diabetes duration 20.5 ± 9.8 years; HbA1c 8.2% ± 1.4%) and 69 with T2D (BMI: 30.8 ± 4.6 kg/m; diabetes duration: 11.7 ± 7.8 years; HbA1c: 7.3% ± 1.4%) were included. Liver fat fraction and stiffness were examined by magnetic resonance imaging and elastography, respectively. Logistic regressions were used to evaluate associations with biomedical variables.
Results: The mean liver stiffness score in patients with obesity and T1D was 2.2 ± 0.5 kPa, while in T2D it was 2.6 ± 0.8 kPa (P < .001). The liver fat fraction in patients with obesity and T1D was 3.7% ± 6.3%, and in T2D it was 10.6% ± 7.9% (P < .001). Metabolic dysfunction-associated steatotic liver disease (MASLD) was present in 13.3% of patients with T1D and in 69.6% of patients with T2D, whereas fibrosis was suggested in 7.8% of patients with T1D and in 27.5% of patients with T2D. Liver stiffness was four times higher in patients with T2D compared with those with T1D (odds ratio = 5.4, 95% confidence interval: 2.1-13.6, P < .001). Aspartate transaminase (AST), alanine transaminase, gamma-glutamyl transferase (GGT), triglycerides and the android-to-gynoid ratio were associated with elevated fat fraction in both cohorts. AST and GGT were associated with elevated liver stiffness in both cohorts.
Conclusions: Patients with obesity and T1D had lower liver fat and liver stiffness compared with those patients with T2D, despite similar levels of BMI, a longer duration of diabetes and worse glycaemic control.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dom.15760 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: This study aimed to evaluate the predictive validity and discriminatory ability of clinical outcomes, inflammatory activity, oxidative and vascular damage, and metabolic mechanisms for detecting significant improve maximum heart rate after physical activity training in individuals with psychiatric disorders and obesity comorbid using a longitudinal design and transdiagnostic perspective.
Methods: Patients with major depressive disorder, bipolar disorder and, schizophrenia and with comorbid obesity (n = 29) were assigned to a 12-week structured physical exercise program. Peripheral blood biomarkers of inflammation, oxidative stress, vascular mechanisms, and metabolic activity, as well as neurocognitive and functional performance were assessed twice, before and after intervention.
Depression and Obesity.
Curr Obes Rep
January 2025
Cleveland Clinic Metabolic and Bariatric Institute, Cleveland, OH, USA.
To summarize the recent literature regarding the interaction between the public health concerns of obesity and depression and provide preliminary recommendations for assessment and management of patients with co-occurring obesity and depression. RECENT FINDINGS : Recent studies have reinforced that while there is a bi-directional link between obesity and depression, there is stronger evidence that obesity contributes to the development of depression. Recent research has also elucidated potential mediating factors in the association between depression and obesity (e.
View Article and Find Full Text PDFThe Effect of Metabolic Bariatric Surgery on Cardiovascular Risks: A Prospective Study Measuring Antibodies to Apolipoprotein A-1.
Obes Surg
January 2025
Cairo University Hospitals, Cairo, Egypt.
Background: Obesity is a chronic disease associated with other associated medical problems, including atherogenic dyslipidemia. Metabolic bariatric surgery (MBS) has been shown to reduce long-term cardiovascular risk (CVR). Anti-ApoA-1 antibodies (AAA1) are independently associated with cardiovascular disease, which remains a major cause of death in individuals with obesity.
View Article and Find Full Text PDFInfluence of BMI on robotic rectal cancer surgery: a systematic review and meta-analysis.
J Robot Surg
January 2025
University of Wisconsin-Madison, Madison, WI, USA.
Obesity presents a significant public health challenge, known to escalate the risk of colorectal cancer twofold. The potential advantages of employing robotic technology in colorectal surgery for obese individuals remain mostly unexplored. A comprehensive search of articles retrieved from Scopus, PubMed, and the Cochrane Library for the duration of January 2014 to March 2024 was performed, without language limitations.
View Article and Find Full Text PDFCardiovascular effects of tirzepatide.
J Endocrinol
January 2025
S Zoungas, School of Public Health and Preventive Medicine, Monash University Faculty of Medicine Nursing and Health Sciences, Melbourne, Australia.
Tirzepatide is a first-in-class dual agonist at receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) for the treatment of T2D and obesity with unprecedented efficacy for glycaemic control and reductions in body weight as well as improvements in blood pressure and lipid profile compared with placebo and GLP-1 receptor agonists. To date, clinical trials of tirzepatide have fulfilled the requirement by regulatory authorities of demonstrated cardiovascular safety in high-risk patients. Whether cardiovascular benefits will be found with dual GLP-1/GIP receptor agonists remains uncertain, and the contribution of GIP receptor activation to cardiovascular risk has not been established.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!